Last year, the Food & Drug Administration gave its blessing to 53 new molecular entities and dozens of new indications for existing prescription products. Among the new releases were some major advances for your patients in the treatment of AIDS, cancer, asthma, diabetes, infections, schizophrenia, and heart disease.
This record crop of approvals was nourished by an accelerated system for reviewing New Drug Applications that saw the mean approval times for new drugs fall from 29.9 months in 1992 to 15.5 months in 1996, according to Pharmaceutical Research & Manufacturers of America (PhRMA).
What has helped to quicken the NDA approval pace is $327 million in user …